TBF is specialized in tissue engineering, offering a comprehensive range of bone substitutes for clinical needs in implantology and maxillofacial surgery. The company provides human-derived bone grafts that are treated for safety and effectiveness.

DePuy Synthes is a medical technology company that focuses on innovations in orthopaedic surgery, support, and education for providers. It is part of the Johnson & Johnson MedTech group.

DePuy Synthes

Geistlich specializes in the regeneration of bone, cartilage and tissue. The company's regenerative medical devices aim to improve patients’ quality of life.

Geistlich Pharma AG

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Metric
Company Name	TBF	DePuy Synthes	Geistlich Pharma AG	Medtronic plc
Symbol				MDT
MSH ID	COM:TBF-LAB	COM:DEPUYSYNTHES	COM:GEISTLICH	COM:MEDTRONIC
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical Devices	Medical Technology	Medical Devices	Medical - Devices
Country	FR	US	CH	IE
Stage
Employee Count				95K
Website	tbf-lab.com	depuysynthes.com	geistlich.com	medtronic.com
LinkedIn
Founders

Metric
Market Cap		98.81B
Enterprise Value
Monthly Web Traffic	293	2.66M
Web Traffic Growth	-0.88	0.29
Valuation
Raised Capital

Metric
Revenue				32.36B
Revenue (LTM)
Revenue (NTM)
Gross Profit				19.45B
EBITDA				8.38B
Operating Income				5.73B
Net Income				3.68B
EPS				2.77
Diluted EPS				2.76
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.66
Operating Profit Margin				0.18
EBITDA Margin				0.26
Net Profit Margin				0.13
Return on Equity				0.08
Return on Assets				0.05
Return on Capital Employed				0.07

TBF-

COM:TBF-LAB

TBF

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				28.22
P/B Ratio				2.25
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				3.63
EV Multiple				12.19

Metric
Days Sales Outstanding				67.78
Days Payables Outstanding				71.76
Days Inventory Outstanding				187.43
Operating Cycle				254.83
Cash Conversion Cycle				189.62
Asset Turnover				0.36

Metric
Operating Cash Flow				6.79B
Free Cash Flow				5.20B
Cash Flow to Debt				0.27
Operating Cash Flow/Sales				0.21
Free Cash Flow Yield				0.03

Metric
Cash & Equivalents				1.28B
Accounts Receivable				-391M
Inventory				5.22B
Goodwill				40.99B
Debt to Capitalization				0.37
Debt to Assets				0.28
Current Ratio				2.29
Quick Ratio				1.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.01
R&D to Revenue				0.08
SG&A to Revenue